GSK wins US shingles vaccine approval, UK nod for gene therapy – Reuters
Proactive Investors UK |
GSK wins US shingles vaccine approval, UK nod for gene therapy
Reuters It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease — a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene … GSK gets approvals for 'bubble boy' syndrome gene therapy in UK and shingles vaccine in US |
